Fahar Merchant
Directeur Général chez MEDICENNA THERAPEUTICS CORP.
Fortune : 8 M $ au 30/06/2024
Profil
Fahar Merchant is the founder of Avicenna Medica, Inc. (founded in 2000), Intelligene Expressions, Inc. (founded in 1992), Medicenna Therapeutics, Inc. (founded in 2012), and Medicenna Therapeutics Corp.
(founded in 2015).
Dr. Merchant is currently the Director at Aries Biologics, Inc. (since 2002).
Merchant was formerly the President & Chief Executive Officer at Sophiris Bio, Inc. (2005-2011), the Chief Technology Officer & Director at KS Biomedix Plc (2001-2003), and the President at KS Avicenna, Inc. (2001-2002).
Merchant received a doctorate degree from the University of Western Ontario in 1986 and an undergraduate degree from the University of Birmingham.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 03/06/2024 | 5 762 802 ( 7,56% ) | 8 M $ | 30/06/2024 |
Postes actifs de Fahar Merchant
| Sociétés | Poste | Début |
|---|---|---|
| MEDICENNA THERAPEUTICS CORP. | Directeur Général | 02/02/2015 |
| Aries Biologics, Inc. | Directeur/Membre du Conseil | - |
Medicenna Therapeutics, Inc.
 Medicenna Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Medicenna Therapeutics, Inc. develops and commercializes therapeutics for the treatment of central nervous system and urological cancers. It also develops proprietary therapeutic cytokines called Superkines, Superkines is powerful immune-system modulators that have significant therapeutic potential for the treatment of many forms of cancer and selected other diseases. Superkines can be fused to tumor cell-killing payloads to form Medicenna's proprietary Empowered Cytokines (EC's). The firm's EC's are being developed for the targeted treatment of cancer and are potentially vastly superior alternatives to other targeted cancer therapies such as Antibody Drug Conjugates. The company was founded by Fahar Merchan and Rosemina Merchant in 2011 and is headquartered in Vancouver, CA. | Directeur Général | 01/10/2012 |
Anciens postes connus de Fahar Merchant
| Sociétés | Poste | Fin |
|---|---|---|
| SOPHIRIS BIO | Directeur Général | 18/04/2011 |
| KS Biomedix Plc | Directeur Technique/Scientifique/R&D | 01/01/2003 |
| KS Avicenna, Inc. | President | 01/06/2002 |
Avicenna Medica, Inc.
 Avicenna Medica, Inc. Electronic Equipment/InstrumentsElectronic Technology Part of Xenova KS Ltd., Avicenna Medica, Inc. develops and provides cytotoxic agent delivery products. The Canadian company was founded by Fahar Merchant. Avicenna Medica was acquired by K.S. Biomedix Holdings Plc on July 13, 2001 for $58.72 million. | Fondateur | 01/07/2001 |
| Intelligene Expressions, Inc. | Fondateur | 01/07/2001 |
Formation de Fahar Merchant
| University of Western Ontario | Doctorate Degree |
| University of Birmingham | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| MEDICENNA THERAPEUTICS CORP. | Health Technology |
| Entreprise privées | 7 |
|---|---|
Sophiris Bio, Inc.
 Sophiris Bio, Inc. Pharmaceuticals: MajorHealth Technology Sophiris Bio, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of products for the treatment of urological diseases. The company was founded by James L. Heppell in May 2003 and is headquartered in La Jolla, CA. | Health Technology |
Avicenna Medica, Inc.
Avicenna Medica, Inc. Electronic Equipment/InstrumentsElectronic Technology Part of Xenova KS Ltd., Avicenna Medica, Inc. develops and provides cytotoxic agent delivery products. The Canadian company was founded by Fahar Merchant. Avicenna Medica was acquired by K.S. Biomedix Holdings Plc on July 13, 2001 for $58.72 million. | Electronic Technology |
| KS Biomedix Plc | |
| Aries Biologics, Inc. | |
| KS Avicenna, Inc. | |
| Intelligene Expressions, Inc. | |
Medicenna Therapeutics, Inc.
Medicenna Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Medicenna Therapeutics, Inc. develops and commercializes therapeutics for the treatment of central nervous system and urological cancers. It also develops proprietary therapeutic cytokines called Superkines, Superkines is powerful immune-system modulators that have significant therapeutic potential for the treatment of many forms of cancer and selected other diseases. Superkines can be fused to tumor cell-killing payloads to form Medicenna's proprietary Empowered Cytokines (EC's). The firm's EC's are being developed for the targeted treatment of cancer and are potentially vastly superior alternatives to other targeted cancer therapies such as Antibody Drug Conjugates. The company was founded by Fahar Merchan and Rosemina Merchant in 2011 and is headquartered in Vancouver, CA. | Health Technology |
